https://www.selleckchem.com/products/sr18662.html
007) decreased in patients receiving active tDCS, compared to the sham group. The therapeutic gain of tDCS was calculated as 44% (95% confidence interval [CI] 22-60%) for headache days and 76% (95% CI 55-86) for headache duration. Response to tDCS treatment was higher in patients without allodynia (60% vs. 24%; p=0.028) and allodynia came out as an independent predictor of response to tDCS with logistic regression analysis. Side effects were rare and similar to the sham group. tDCS is a safe, efficacious, and fast method for migraine pr
Like
Comment
Share
